相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas
Lawrence A. Donehower et al.
CELL REPORTS (2019)
The role of MDM2 amplification and overexpression in therapeutic resistance of malignant tumors
Helei Hou et al.
CANCER CELL INTERNATIONAL (2019)
The past, present and future of potential small-molecule drugs targeting p53-MDM2/MDMX for cancer therapy
Yao Liu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
475PA phase IIa clinical trial combining ALRN-6924 and palbociclib for the treatment of patients with tumours harboring wild-type p53 and MDM2 amplification or MDM2/CDK4 co-amplification
F Meric-Bernstam et al.
ANNALS OF ONCOLOGY (2019)
Brain Distributional Kinetics of a Novel MDM2 Inhibitor SAR405838: Implications for Use in Brain Tumor Therapy
Minjee Kim et al.
DRUG METABOLISM AND DISPOSITION (2019)
MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment
Douglas D. Fang et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours
Vincent A. de Weger et al.
BRITISH JOURNAL OF CANCER (2019)
COSMIC: the Catalogue Of Somatic Mutations In Cancer
John G. Tate et al.
NUCLEIC ACIDS RESEARCH (2019)
Inhibition of p53 inhibitors: progress, challenges and perspectives
Gema Sanz et al.
JOURNAL OF MOLECULAR CELL BIOLOGY (2019)
Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition
Jo Ishizawa et al.
CANCER RESEARCH (2018)
Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood-Brain Barrier
Minjee Kim et al.
MOLECULAR CANCER THERAPEUTICS (2018)
A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours
Maja de Jonge et al.
EUROPEAN JOURNAL OF CANCER (2017)
MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer
Veronica Tisato et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapy: Progress and Challenges
Shaomeng Wang et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2017)
Putting p53 in Context
Edward R. Kastenhuber et al.
CELL (2017)
Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia
Michael Andreeff et al.
CLINICAL CANCER RESEARCH (2016)
Correlating chemical sensitivity and basal gene expression reveals mechanism of action
Matthew G. Rees et al.
NATURE CHEMICAL BIOLOGY (2016)
ROBUST HYPERPARAMETER ESTIMATION PROTECTS AGAINST HYPERVARIABLE GENES AND IMPROVES POWER TO DETECT DIFFERENTIAL EXPRESSION
Belinda Phipson et al.
ANNALS OF APPLIED STATISTICS (2016)
Reactivation of p53 by MDM2 Inhibitor MI-77301 for the Treatment of Endocrine-Resistant Breast Cancer
Jianfeng Lu et al.
MOLECULAR CANCER THERAPEUTICS (2016)
TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma
Joonil Jung et al.
NATURE COMMUNICATIONS (2016)
Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastoma
Jiaxiong Lu et al.
ONCOTARGET (2016)
Tumor-Suppressor Functions of the TP53 Pathway
Brandon J. Aubrey et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2016)
The Cell-Cycle Arrest and Apoptotic Functions of p53 in Tumor Initiation and Progression
Jiandong Chen
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2016)
The Role of MDM2 Amplification and Overexpression in Tumorigenesis
Jonathan D. Oliner et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2016)
Lollipops in the Clinic: Information Dense Mutation Plots for Precision Medicine
Jeremy J. Jay et al.
PLOS ONE (2016)
MDM2 antagonist clinical response association with a gene expression signature in acute myeloid leukaemia
Hua Zhong et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Elucidation of Acquired Resistance to Bcl-2 and MDM2 Inhibitors in Acute Leukemia In Vitro and In Vivo
C. Gianna Hoffman-Luca et al.
CLINICAL CANCER RESEARCH (2015)
limma powers differential expression analyses for RNA-sequencing and microarray studies
Matthew E. Ritchie et al.
NUCLEIC ACIDS RESEARCH (2015)
Significant Differences in the Development of Acquired Resistance to the MDM2 Inhibitor SAR405838 between In Vitro and In Vivo Drug Treatment
C. Gianna Hoffman-Luca et al.
PLOS ONE (2015)
Anti-tumor activity of the TGF-β receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts
Armin Maier et al.
CELLULAR ONCOLOGY (2015)
Novel Insights into the Molecular Mechanisms Governing Mdm2 Ubiquitination and Destruction
Oncotarget (2015)
SAR405838: An Optimized Inhibitor of MDM2-p53 Interaction That Induces Complete and Durable Tumor Regression
Shaomeng Wang et al.
CANCER RESEARCH (2014)
Mutational landscape and significance across 12 major cancer types
Cyriac Kandoth et al.
NATURE (2013)
Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells
Wanjuan Yang et al.
NUCLEIC ACIDS RESEARCH (2013)
Qualimap: evaluating next-generation sequencing alignment data
Fernando Garcia-Alcalde et al.
BIOINFORMATICS (2012)
A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3
Pablo Cingolani et al.
FLY (2012)
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Jordi Barretina et al.
NATURE (2012)
clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters
Guangchuang Yu et al.
OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY (2012)
A statistical framework for SNP calling, mutation discovery, association mapping and population genetical parameter estimation from sequencing data
Heng Li
BIOINFORMATICS (2011)
Jetset: selecting the optimal microarray probe set to represent a gene
Qiyuan Li et al.
BMC BIOINFORMATICS (2011)
A framework for variation discovery and genotyping using next-generation DNA sequencing data
Mark A. DePristo et al.
NATURE GENETICS (2011)
Fast and accurate long-read alignment with Burrows-Wheeler transform
Heng Li et al.
BIOINFORMATICS (2010)
PICNIC: an algorithm to predict absolute allelic copy number variation with microarray cancer data
Chris D. Greenman et al.
BIOSTATISTICS (2010)
The Sequence Alignment/Map format and SAMtools
Heng Li et al.
BIOINFORMATICS (2009)
Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction to Reactivate p53 Function: A Novel Approach for Cancer Therapy
Sanjeev Shangary et al.
Annual Review of Pharmacology and Toxicology (2008)
MDM2 and MDM4: p53 regulators as targets in anticancer therapy
Franck Toledo et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2007)
Regulating the p53 pathway:: in vitro hypotheses, in vivo veritas
Franck Toledo et al.
NATURE REVIEWS CANCER (2006)
The consensus coding sequences of human breast and colorectal cancers
Tobias Sjoeblom et al.
SCIENCE (2006)
Anticancer metal compounds in NCI's tumor-screening database: putative mode of action
RL Huang et al.
BIOCHEMICAL PHARMACOLOGY (2005)
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2
LT Vassilev et al.
SCIENCE (2004)
Inhibiting the p53-MDM2 interaction:: An important target for cancer therapy
P Chène
NATURE REVIEWS CANCER (2003)
分享论文
